Autoantibodies to phospholipids (APA) occur frequently in systemic lupus erythematosus (SLE) and other autoimmune disorders and predispose to intravascular thromboses. Major histocompatibility complex (MHC) class II alleles (HLA-DR and DQ) were determined by restriction fragment length polymorphisms (RFLP) in 20 patients with APA (lupus anticoagulant). HLA-DQw7 (DQB1 *0301), linked to HLA-DR5 and -DR4 haplotypes, occurred in 70% and was significantly increased compared to 139 race-matched normal controls (P = 0.002, P corrected Ipci = 0.05, odds ratio [OR] = 5.1). Moreover, the frequency of HLA-DQw7 was significantly higher in SLE patients with APA as compared with patients without APA but with other autoantibodies, including anti-Ro and La (P = 0.0001, pc = 0.002, OR = 10.7), anti-Ro alone (P = 0.001, pc = 0.02, OR = 11.2), anti-dsDNA (P = 0.001, pc = 0.02, OR = 7.1), and possibly anti-Sm (P = 0.04, pc = NS, OR = 6.8) and anti-nRNP (U1-RNP) (P = 0.01, pc = NS, OR = 7.8). The DQB1 *0301 allele of DQw7 showed the strongest association, while the frequencies of the DQA1 *0301 (45%) and DQA1 *0501 (50%) alleles did not differ from the controls. Among the HLA-DQB1
less often, in those with other connective tissue diseases (reviewed in reference 1). Although recognized for many years as the cause for a biologic false-positive (BFP) test for syphilis and a circulating lupus anticoagulant (2, 3) , and, more recently, by anticardiolipin assays (4) , their clinical relevance to disease manifestations is only now being appreciated. Recent studies indicate strong correlations of APA with intravascular thromboses, recurrent spontaneous abortions, Libman-Sack's endocarditis, and livido reticularis (1, 5) . Moreover, a causative role for these antibodies in these disease complications seems likely. A "primary antiphospholipid syndrome" has even been proposed based on patients presenting with these clinical features in association with anticardiolipin antibodies or a lupus anticoagulant who do not fulfill criteria for SLE or other connective tissue disease (5, 6) . In fact, APA have been detected in 3-4% of patients presenting with strokes (7, 8) , and we have found recently a 9% prevalence ofthe lupus anticoagulant in 100 consecutive patients admitted to a neurology service.
SLE is a clinically and serologically heterogeneous disease in which genetic factors appear to play important roles. HLA-DR2 and HLA-DR3 each show weak associations with SLE (9, 10); however, stronger HLA class II correlations have been found for several autoantibodies expressed in SLE patients (1 1-1 3). Such findings suggest that these autoimmune responses, some of which may play direct pathogenetic roles, are genetically mediated by antigen-specific T helper lymphocytes (14) .
The purpose of this study was to determine whether any HLA-DR and/or -DQ alleles were associated with antiphospholipid antibodies as defined by the presence of a circulating lupus anticoagulant. Moreover, immunogenetic differences were sought between connective tissue disease patients expressing the lupus anticoagulant and those, especially with SLE, having other autoantibody profiles. HLA-DR and -DQ alleles were defined at the DNA level using restriction fragment length polymorphisms (RFLP), so as to more precisely define the specific alleles and potential nucleotide (and their inferred amino acid) sequences associated with this autoimmune response. for anti-Ro (SS-A) but not anti-La (SS-B) (d) 57 patients (32 white and 25 black) with SLE or Sjogren's syndrome who were positive for antiRo and anti-La, and (e) 53 patients with SLE positive for high-titer anti-dsDNA antibodies. Because we were studying autoantibody subsets, it should be noted that patients with multiple autoantibodies could be represented in more than one of the above groups.
Methods
Normal controls included 79 local Caucasian and 60 local black volunteers who were blood donors or medical school personnel whose HLA-DR and -DQ alleles were similarly defined by RFLP analyses.
Autoantibody determinations. The lupus anticoagulant was defined by the tissue thromboplastin inhibition test (Sigma Chemical Co., St. Louis, MO) performed on freshly drawn citrated blood in the clinical laboratory. In addition, 16 of the 20 lupus anticoagulant positive patients had a prolonged activated partial thromboplastin time which did not correct with a 1:1 mix with fresh normal human plasma.
Antibodies to Sm, nRNP (U I-RNP), and La were detected by countercurrent immunoelectrophoresis against calf thymus and antiRo against human spleen extracts using our modifications (15) of the method of Johnson et al. (16) . Antibodies to double-stranded DNA (dsDNA) were determined by indirect immunofluorescence using Crithidia luciliae as antigen substrate (17) and by ELISA using calf thymus DNA (Sigma Chemical Co.). Only those with titers 2 1/160 on Crithidia luciliae and high levels ofbinding in ELISA were included in the anti-dsDNA positive group.
RFLP analysis of HLA-DR and DQ alleles. Genomic DNA was extracted from peripheral blood leukocytes (18) and 10 ug digested with the restriction endonucleases Bam HI and Taq I under conditions specified by the manufacturer, and then electrophoresed through 0.8% agarose gel overnight at 50 V. The gel was then stained in ethidium bromide, photographed, and subjected to denaturation and neutralization as described previously (19) , and transferred onto Zetabind membranes (Cuno Inc., Meriden, CT).
Probes used in this study included a 770 bp Sac I/Hind III-cut full-length DRB1 cDNA (20) , a 700-bp full-length Pst I-cut DQB1 cDNA (21) , and a 2.4-kb genomic Pst I-cut DQAI probe (22) , which were radiolabeled with aCTP32 by oligolabeling (23) . Prehybridization and hybridization conditions were carried out as previously described ( 19) .
HLA-DR and -DQ specificities were assigned to specific RFLP bands at the 10th International Histocompatibility Testing Workshop (24) , as well as in our own (25, 26) and others' studies (27-32). Specific DQA1 and DQB1 chain alleles in each individual were assigned by comparison with reported DQA1 and DQB1 RFLP's for specific HLA-D haplotypes as determined by the World Health Organization Nomenclature Committee for factors of the HLA system which met during the 7th International Congress of Immunology in 1989 (33).
Statistical analyses. Comparisons of HLA phenotype frequencies in lupus anticoagulant positive patients versus normal race-matched controls and other autoantibody subsets were performed using MantelHaenszel chi-square analysis which combined the 2 X 2 tables for each race using the EPISTAT statistical program. P values were corrected for the number of HLA specificities examined. Relative risks were calculated as odds ratios, also using the Mantel-Haenszel method. Therefore, the odds ratios reported represent an averaged risk for combined white and black patients as compared to their respective combined race-matched controls.
Results
Among the 20 patients with a lupus anticoagulant, nine fulfilled the American College of Rheumatology criteria for SLE (34) , eight were considered clinically to have a primary antiphospholipid syndrome (5) (Table I) . These three specificities were typically inherited as a haplotype in nine patients; the one additional DRw52b occurred on a DRw6 (13) haplotype, and the five additional DQw7 specificities were linked to HLA-DR4 haplotypes. All four ofthe black patients were positive for HLA-DR4, DQw7 haplotypes. Among the 10 HLA-DR4 positive normal black controls, only three (30%) were linked to DQw7 and the remainder (70%) to DQw8 (P = 0.07, Fisher's exact test, two-tailed, for comparison of DQw7 linkage to DR4 in black patients versus black controls). Thus, in both whites and blacks HLA-DQw7 was the most common of these associated specificities (70%) and was the only one which maintained statistical significance after correction for multiple comparisons (Table I) . Among the six HLA-DQw7-negative patients, one was an HLA-DR4, -DQw8 homozygote, and the remaining five were HLA-DQw6 heterozygotes, including two with HLA-DQw8 and one with -DQw9 on the alternative haplotype. Thus, all patients with the lupus anticoagulant were positive for HLA-DQw7, -DQw8 or -DQw6.
Lupus anticoagulant positives versus other autoantibody subgroups. HLA-DR5, -DRw52b (Dw25), and -DQw7 were all increased in patients with a lupus anticoagulant compared to those with anti-Sm (with or without accompanying anti-Ul-RNP), anti-U l-RNP without anti-Sm, anti-Ro without antiLa, anti-Ro and -La, and anti-dsDNA antibodies (Table II) .
A significant association of HLA-DQw7 was maintained in lupus anticoagulant positives as compared to anti-Ro, anti-La, and anti-dsDNA positives after correction ofP values for multiple comparisons, whereas HLA-DR5 and -DRw52b lost significance (except for DR5 and anti-Ro and -La). Moreover, HLADQw7 conferred the highest odds ratios for the lupus anticoagulant versus each of the other autoantibody subgroups.
HLA-DQAI and -DQBI alleles in patients with the lupus anticoagulant. HLA-DQA1 and -DQB 1 chain alleles comprising the DQw7 specificity were then determined from the RFLP patterns (32) ( (39) . For the anti-Sm and anti-nRNP (U1-RNP) responses, HLA-DQB1 codon (amino acid) position 57 appears to be critical (40) . AntidsDNA antibodies are associated with the HLA-DRB I * 0201, DRBI *0602, and DQB1 * 0302 alleles, each of which bears a methionine in position 14 and a leucine in position 26 (41) .
This study used a similar molecular approach to determine whether any HLA-DR or -DQ alleles were associated with antiphospholipid antibodies, as defined by a circulating lupus anticoagulant. Indeed, HLA-DR5, -DRw52b (Dw25), and -DQw7, which occur in linkage disequilibrium as a haplotype, were each increased in patients with the lupus anticoagulant as compared to race-matched normal controls. Ofthese alleles, HLADQw7 was most commonly present (70%) and occurred on HLA-DR5 and/or HLA-DR4 haplotypes. Moreover, HLADQw7 was significantly increased in lupus anticoagulant positive patients when compared to those with anti-Ro, anti-La, anti-dsDNA, and possibly anti-Sm (±anti-U 1-RNP) and anti-U1-RNP alone, whereas HLA-DR5 and DRw52b tended to lose significance when P values were corrected for multiple comparisons.
There are two previous studies ofHLA antigen frequencies, detected serologically, in patients with APA. Savi et al. (42) reported an increase of HLA-DR7 in Italian patients and McHugh and Maddison (43) an excess ofHLA-DR4 in United Kingdom patients with SLE and anticardiolipin antibodies. In neither report were HLA-DQ frequencies described. In our study, all of the patients with HLA-DQw7 were HLA-DR4 or -DR5 positive. It may be notable that HLA-DR4 is in linkage disequilibrium with HLA-DQw7, whereas HLA-DR7 is not. HLA-DRw53 is linked to both -DR4 and -DR7; however, this allele was not significantly increased in our patients. Therefore, it appears likely that HLA-DQw7 is the most relevant allele; however, we cannot exclude the possibility of an effect(s) from HLA-DR5 and/or HLA-DRw52b (Dw25). Moreover, our study population was small and these results must be viewed as preliminary.
Because HLA-DQ molecules are comprised of polymorphic DQa and DQB chains, we then ascertained specific DQA 1 and DQB1 alleles from RFLP patterns as defined by the 7th International Congress of Immunology in 1989 (33) . All of the HLA-DQw7 positives with the lupus anticoagulant possessed the DQBI *0301 allele which defines DQw7. HLA-DQA1 *0301, which may occur on DR4, DQw7; DR4, DQw8; or DR9, DQw9 haplotypes was found in nine (45%) of the patients and was not significantly increased when compared with normal control frequencies. Similarly, HLA-DQA1 *0501 which may occur on HLA-DR5 (DRwl 1 and DRwl2), DQw7; DR3 (DRwl7), DQw2; DRw6 (DRw14), DQw7; and DR2, DQw7 haplotypes occurred in 50% of the patients but was not significantly increased. Thus, HLA-DQB1 *0301 appears to show the strongest association with the autoimmune response producing the lupus anticoagulant. The HLA-DQ specificities found in the HLA-DQw7-negative patients with the lupus anticoagulant may provide clues to the region of the HLA-DQ molecule involved in this autoimmune response. Interestingly, one patient was homozygous for HLA-DQw8 and the remainder were heterozygous for HLADQw6. Three ofthese latter patients were also heterozygous for HLA-DQw8 or -DQw9. It seems unlikely that the HLA-DQA I alleles of-DQw7, -DQw6, and -DQw8 are primarily involved, because their amino acid sequences are quite different (32, 33) . On the other hand, the HLA-DQB 1 alleles of -DQw7 (DQB I * 0301), -DQw6 (DQB I * 0602, *0601, *0603 and *0604), -DQw8 (DQB 1* 0302) as well as -DQw9 (DQB 1 * 0303), share a common amino acid sequence (positions 71-77) in the third hypervariable region of the outermost domain (14, 29, 33) (Table IV) . This DQB1 sequence, TRAELDT, is distinct from those found in the DQB 1 alleles of HLA-DQw2, -DQw4, and -DQw5 and, as such, may represent an autoantibody predisposing "epitope". Based upon the hypothetical model for MHC class II three-dimensional structure proposed by Brown et al. (44) , this sequence should map to the DQB alpha helical region where it would be in a position to potentially bind the T cell antigen receptor. It will not be certain, however, where this sequence maps until the structures ofclass II molecules are definitively known. Moreover, in other diseases, such as rheumatoid arthritis and insulin-dependent diabetes mellitus, where particular amino acid sequences are implicated in disease, the alleles sharing these sequences are independently associated with the diseases (14, 37) . It should be emphasized that, thus far, this is not the case for the lupus anticoagulant. HLA-DQw7 occurred more commonly in this population of patients with this antibody than did -DQw8 or -DQw6, despite the sharing of the same candidate -DQB I sequences. Thus, there may be other relevant sequences and/or conformational determinants in the DQw7 molecule which more strongly promote this abnormal immune response. We did not find any HLA-DQ specificities that appeared "protective" (two patients had -DQw4, three -DQw5, and six -DQw2). Additional studies will be needed to determine whether this third hypervariable region sequence is the "epitope" which preferentially binds the currently unknown antigen responsible for the immune response resulting in a lupus anticoagulant.
It should be emphasized that we did not measure APA by cardiolipin assays but rather by the presence ofa lupus anticoagulant. Therefore, additional studies will be necessary to determine whether the association of HLA-DQw7 
